Acute Ischemia Stroke
Conditions
Interventions
Experimental group:Tirofiban + Antiplatelet therapy
Control group:Antiplatelet therapy
Sponsors
The Second People's Hospital of Chengdu
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years; 2. Brain CT, MRI or DWI diagnosed as acute ischemic stroke; 3. Moderate to severe acute ischemic stroke patients: NIHSS score 4-18; 4. Predictive factors of BAD: proximal vascular occlusion, DWI-PWI mismatch, no recanalization, low brainstem infarction, branch atherosclerotic disease, posterior lenticulostriate infarction, single small subcortical infarction, etc. ; 5. Within 48 hours after onset (The time of onset is defined as the time when the subject has symptoms of neurological deficit. If the time of onset is not clear, the time of onset is defined as the time when the subject has clearly not yet developed the disease before the onset), subjects who failed to undergo revascularization therapy beyond the treatment time window; 6. Subjects gave informed consent, participated voluntarily, and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those with cardiac pacemaker implantation, severe weakening of heart, lung, liver and kidney functions, malignant tumors, various bleeding diseases, coagulation disorders, acute infectious diseases, high fever diseases, women's menstrual period or pregnancy, etc.; 2. Patients who are taking coagulation drugs; 3. Patients who are participating in other clinical studies; 4. Patients with severe hypersensitivity to tirofiban.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whether the degree of stroke has progressed;90-day prognosis good; | — |
Countries
China
Contacts
Public ContactWang Jian
The Second People's Hospital of Chengdu
Outcome results
None listed